Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. covers the month of September 2019. The report primarily announces a corporate governance update regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a report of a specific corporate event rather than a financial statement.
Material Changes
The material change reported is the appointment of Dr. Shmuel Cabilly, PhD, to the Company's Board of Directors, effective September 22, 2019. Dr. Cabilly previously served on the Board from August 2010 until June 2019 and also served on the compensation committee until that date.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It focuses solely on the reappointment of Dr. Cabilly, highlighting his background as a scientist and inventor in immunology, including his work on the "Cabilly Patent" and dry buffer technologies.
Key Facts for Investor Verification
- Dr. Shmuel Cabilly was reappointed to the Board of Directors effective September 22, 2019.
- Dr. Cabilly's term continues until the Company's next annual general meeting.
- The filing incorporates by reference into various Registration Statements on Forms S-8 and F-3.
- No financial performance data is included in this specific report.